Equities analysts expect Invuity, Inc. (NASDAQ:IVTY) to announce earnings of ($0.51) per share for the current quarter, according to Zacks. Four analysts have made estimates for Invuity’s earnings, with the highest EPS estimate coming in at ($0.45) and the lowest estimate coming in at ($0.55). Invuity posted earnings of ($0.64) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 20.3%. The business is scheduled to report its next quarterly earnings report on Wednesday, April 25th.
On average, analysts expect that Invuity will report full year earnings of ($1.82) per share for the current financial year, with EPS estimates ranging from ($1.98) to ($1.73). For the next fiscal year, analysts expect that the firm will post earnings of ($1.41) per share, with EPS estimates ranging from ($1.73) to ($1.05). Zacks’ earnings per share averages are an average based on a survey of analysts that that provide coverage for Invuity.
Invuity (NASDAQ:IVTY) last released its quarterly earnings results on Tuesday, February 13th. The medical instruments supplier reported ($0.43) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.50) by $0.07. The company had revenue of $11.23 million for the quarter, compared to the consensus estimate of $11.84 million. Invuity had a negative net margin of 100.75% and a negative return on equity of 380.14%.
IVTY has been the topic of a number of recent research reports. Zacks Investment Research raised shares of Invuity from a “hold” rating to a “buy” rating and set a $6.00 price target on the stock in a research note on Saturday, January 27th. Northland Securities reaffirmed a “buy” rating and set a $6.00 price target on shares of Invuity in a research note on Wednesday, February 14th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $8.50.
Institutional investors have recently added to or reduced their stakes in the stock. Eversept Partners LLC purchased a new stake in Invuity during the fourth quarter valued at $279,000. Vanguard Group Inc. increased its position in Invuity by 16.3% during the second quarter. Vanguard Group Inc. now owns 402,680 shares of the medical instruments supplier’s stock valued at $2,919,000 after acquiring an additional 56,527 shares during the last quarter. Discovery Group I LLC increased its position in Invuity by 9,587.9% during the third quarter. Discovery Group I LLC now owns 1,258,849 shares of the medical instruments supplier’s stock valued at $11,204,000 after acquiring an additional 1,245,855 shares during the last quarter. Lyon Street Capital LLC increased its position in Invuity by 15.5% during the third quarter. Lyon Street Capital LLC now owns 883,355 shares of the medical instruments supplier’s stock valued at $7,862,000 after acquiring an additional 118,825 shares during the last quarter. Finally, Wells Fargo & Company MN increased its position in Invuity by 987.0% during the fourth quarter. Wells Fargo & Company MN now owns 64,198 shares of the medical instruments supplier’s stock valued at $398,000 after acquiring an additional 58,292 shares during the last quarter. 63.59% of the stock is currently owned by institutional investors.
Invuity (IVTY) traded up $0.18 during trading on Tuesday, reaching $4.40. 85,709 shares of the company were exchanged, compared to its average volume of 193,953. The company has a current ratio of 2.55, a quick ratio of 2.47 and a debt-to-equity ratio of -33.85. Invuity has a 52 week low of $3.30 and a 52 week high of $9.70.
COPYRIGHT VIOLATION NOTICE: This piece was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/03/11/analysts-expect-invuity-inc-ivty-to-announce-0-51-earnings-per-share.html.
Invuity, Inc, a medical technology company, develops various surgical devices to address various surgical procedures in the United States. The company integrates its intelligent photonics technology platform into its single-use and reusable advanced surgical devices to address various critical intracavity illumination and visualization challenges.
Get a free copy of the Zacks research report on Invuity (IVTY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Invuity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invuity and related companies with MarketBeat.com's FREE daily email newsletter.